Clinical Trial Update: Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating valganciclovir for HHV-8-associated multicentric Castleman disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castleman Disease
• Hhv-8-associated Multicentric Castleman Disease
• Multicentric Castleman Disease

Drugs mentioned

• Valcyte (valganciclovir)
• Valganciclovir (Valganciclovir)

Snippet

Sponsor: University of Washington | Conditions: Giant Lymph Node Hyperplasia | Phase 4 | Status: WITHDRAWN